|
| 产地 | 中国 |
| 品牌 | Chemstan |
| 货号 | LC-01 |
| 用途 | 中间体 |
| 包装规格 | 20mg |
| 纯度 | 98%% |
| CAS编号 | 185991-07-5 |
| 是否进口 | 否 |
联合知名大学科研院所及企业开发药食两用植物标准品和天然植物有效单体，主打中药对照品/标准品/天然植物有效单体，小分子化合物库，药物杂质。所有产品仅用作科学研究，我们不为任何个人用途提供产品和服务。
| 常用名 | AMD 3465六氢溴化物 | 英文名 | AMD3465 |
|---|---|---|---|
| CAS号 | 185991-07-5 | 分子量 | 896.070 |
| 密度 | 1.022g/cm3 | 沸点 | 571.3oC at 760 mmHg |
| 分子式 | C24H44Br6N6 | 熔点 | N/A |
| MSDS | N/A | 闪点 | 299.3oC |
AMD 3465 hexahydrobromide 是一种有效的，选择性的 CXCR4 拮抗剂，抑制 SDF-1α-配基结合，Ki 值为 41.7 nM。
Fields of Application :
AMD3465 is a Potent, selective CXCR4 antagonist; exhibits 8-fold higher affinity than AMD 3100 (Cat.No. 3299). Inhibits SDF-1α-ligand binding (Ki = 41.7 nM).
| CAS Number: | 185991-07-5 |
| Purity: | >98% |
| Molecular Weight: | 896.07 |
| Molecular Formula: | C24H38N6.6HBr |
Quality Control: HPLC、NMR、 LC/MS(Please contact us to get the QC report)
| Synonyms: | AMD3465,AMD-3465,AMD 3465 |
| Chemical Name: | |
| Storage: | 2 years -20°C Powder, 2 weeks4°C in DMSO,6 months-80°C in DMSO |
Note: Products for research use only, not for human use
Description:
AMD 3465(GENZ-644494) is a potent, selective CXCR4 antagonist; exhibits 8-fold higher affinity than AMD 3100; inhibits SDF-1α-ligand binding (Ki = 41.7 nM). IC50 value: Target: CXCR4 in vitro: AMD3465 is a novel, nonpeptide CXCR4 antagonist and a potent inhibitor of HIV cell entry in that one of the four-nitrogen cyclam rings of the symmetrical, prototype bicyclam antagonist AMD3100 has been replaced by a two-nitrogen N-pyridinylmethylene moiety . AMD3465 is an antagonist of SDF-1 ligand binding (K(i) of 41.7+/-1.2nM), and inhibits SDF-1 mediated signaling as shown by inhibition of GTP binding, calcium flux, and inhibition of chemotaxis. AMD3465 is selective for CXCR4 and does not inhibit chemokine-stimulated calcium flux in cells expressing CXCR3, CCR1, CCR2b, CCR4, CCR5 or CCR7, nor does it inhibit binding of LTB(4) to its receptor, BLT1 . in vivo: The pharmacokinetics of AMD3465 was investigated in mice and dogs. Absorption was rapid following subcutaneous administration. AMD3465 was cleared from dog plasma in a biphasic manner with a terminal half-life of 1.56-4.63h. Comparison of exposure to the intravenous and subcutaneous doses indicated 100% bioavailability following subcutaneous administration. AMD3465 caused leukocytosis when administered subcutaneously in mice and dogs, with peak mobilization occurring between 0.5 and 1.5h following subcutaneous dosing in mice and with maximum peak plasma concentration of compound preceding peak mobilization in dogs, indicating that AMD3465 has the potential to mobilize hematopoietic stem cells .For the detailed information of AMD3465, the solubility of AMD3465 in water, the solubility of AMD3465 in DMSO, the solubility of AMD3465 in PBS buffer, the animal experiment (test) of AMD3465, the cell expriment (test) of AMD3465, the in vivo, in vitro and clinical trial test of AMD3465, the EC50, IC50,and Affinity of AMD3465, Please contact DC Chemicals.
